Paul, Weiss advises DRI Healthcare Trust on its acquisition of a royalty interest in chronic thyroid eye disease treatments from Viridian Therapeutics.
DRI Healthcare Trust acquired the target/assets from Viridian Therapeutics, Inc. in an acquisition on an undisclosed date.
Deal value was 300000000 Sector: Life Sciences; Location: USA.
On the acquirer side, legal representation details are unavailable, but involved lawyers include Jeffrey Osterman and Robert Zochowski.
Generated by AI, original source from - Data is in progress
Viridian Therapeutics, Inc. advisor
Firm name is in progress
Found it useful? Spread the word.
Paul, Weiss advises DRI Healthcare Trust on its acquisition of a royalty interest in chronic thyroid eye disease treatments from Viridian Therapeutics. | The Sponsor - The Sponsor
